Neumora Therapeutics, Inc. (NMRA): Cash & Equivalents
$182.53M
As of 2025-12-31
$116.83M
As of 2026-06-30
-8.8%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $182.53M | +28.4% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $142.15M | -62.0% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $374.04M | +55.2% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $240.94M | n/a | 2025-03-03, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | $182.53M | +28.4% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $146.65M | +11.5% |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $178.80M | +83.4% |
| Instil Bio, Inc. (TIL) | 2025-12-31 | $6.64M | -24.6% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $12.36M | -24.1% |
| Protara Therapeutics, Inc. (TARA) | 2025-12-31 | $49.66M | -69.5% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $58.13M | -69.5% |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $10.50M | +18.0% |
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | $59.52M | +87.8% |
Compare NMRA, EDIT, IKT, TIL side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗